Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women

Last updated: July 26, 2024
Sponsor: Lindenwood University
Overall Status: Terminated

Phase

N/A

Condition

Metabolic Syndrome

Diabetes Prevention

Obesity

Treatment

Exercise

Clinical Study ID

NCT05775016
IRB-23-29
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to examine changes in body composition, weight loss, glucose control, and cardiometabolic risk factors after adding supplementation of BAIBA to exercise in overweight and obese men and women.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants who are between 18 - 60 years of age

  • Body mass index values will range from >25.0 to < 32.0 kg/m2, making them qualifiedas an overweight-to-obese population (https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm)

  • Average body mass index for entire study cohort will be less than 30.0 kg/m2. Assuch an ongoing calculation of the recruited cohort's mean body mass index will bemaintained and people will only be randomized into the study if the average cohortbody mass index value does not exceed 30.0 kg/m2

  • Free-living/uninhibited with use of ambulatory assistive devices (e.g. canes,crutches, walkers, etc.) and independent

  • In good health absent of being overweight or mildly obese with no other signs orsymptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, ormusculoskeletal disease or disorders

  • Willingness to maintain consistent sleep duration the evening before study visits

  • Willing and able to agree to the requirements and restrictions of this study, bewilling to give voluntary consent, and carry out all study-related procedures

  • Able to complete a peak oxygen consumption exercise test with no contraindicationsto perform exercise per standards put forth by the American College of SportsMedicine. In other words, they are able to safety complete maximal exercise.

Exclusion

Exclusion Criteria:

  • Positive medical history and/or is currently being treated for some form of heartdisease, cardiovascular disease

  • Currently being treated for kidney disease, renal failure, or has dialysis performedon regular intervals

  • Has liver disease or some form of clinically diagnosed hepatic impairment

  • Diagnosed with having Type I or Type II diabetes (determined as fasting bloodglucose > 126 mg/dL)

  • Diagnosed with or is being treated for some form of thyroid disease

  • Diagnosed with major affective disorder or other psychiatric disorder that requiredhospitalization in the prior year

  • Diagnosed with some form of immune disorder (i.e., HIV/AIDS)

  • History of cancer (except localized skin cancer without metastases or in situcervical cancer within 5 years prior to screening visit).

  • Participant has an abnormality or obstruction of the gastrointestinal tractprecluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinalmalabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis,steatorrhea)

  • Positive medical history for any neurological condition or neurological disease

  • Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) orany hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers,Vasodilators, etc.)

  • Current smoker (average of > 1 pack per day within the past 3 months) has quitwithin the past six months. This includes all forms of nicotine

  • Intake of any drugs (prescribed or over the counter) or dietary supplements that areknown or are purported to weight loss such as thermogenics, hydroxycitric acid,ephedra, capsaicin, etc.

  • Participants who are lactating, pregnant or planning to become pregnant

  • Have a known sensitivity or allergy to any of the study products

  • History of alcohol or substance abuse in the 12 months prior to screening

  • Receipt or use of an investigational product in another research study within 30days of beginning the study protocol

  • They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel,etc.) during the study

  • Recent history (<3 months) of exercise training or weight loss (> 5%)

  • Any orthopedic limitation that would prevent participation in a general fitnessprogram

  • Any condition or abnormality that, in the opinion of the investigator, wouldcompromise the safety of the participant or the quality of the study data

Study Design

Total Participants: 23
Treatment Group(s): 1
Primary Treatment: Exercise
Phase:
Study Start date:
March 29, 2023
Estimated Completion Date:
April 23, 2024

Study Description

This study will be conducted using a double-blind, placebo-controlled, parallel group design. Eligible study participants will be randomly assigned to one of three supplementation groups: placebo (resistant dextrin) supplementation + exercise group, 750 mg BAIBA supplementation + exercise group, and a 1500 mg BAIBA supplementation + exercise group. After signing an IRB-approved consent form, prospective participants will be scheduled for a screening visit where they will have their eligibility finalized through completion of a peak VO2 assessment using a motorized treadmill and metabolic cart. Eligible participants will then be fully explained the study and scheduled for a baseline testing session (week 0). Prior to scheduling this visit, participants must complete a 4-day food record. Once a food record is completed, participants will observe an overnight fast and be scheduled to complete the testing session between the hours of 0600

  • 1000 hours. Upon arrival, changes in medical status, medications, and dietary supplements will be confirmed before having their body mass and hemodynamics assessed. Next, participants will have their waist circumference, body water (BIS), and body composition (DEXA) assessed to evaluate changes in body composition and obesity status throughout the study protocol. Participants will then have a venous blood sample collected for evaluation of health markers (complete blood counts, comprehensive metabolic panels, and lipid panels) before completing a resting metabolic rate measurement. The resting metabolic rate measurement will be used to prescribe energy intake throughout the study protocol. Participants will then use an electronic tablet and complete the Profile of Mood States and visual analog scales to evaluate perceptions of hunger and appetite. Participants will then be given their first daily dose. All participants will be given instructions and meal plans as well as be offered weekly educational sessions on how to restrict calories and meet protein goals throughout the study protocol. Participants will complete five days per week of exercise consisting of a mixture of walking and resistance training. Daily compliance to the exercise and supplementation groups will be monitored weekly for a 12-week period. Participants who complete at least 80% of their assigned workouts will be considered compliant and will be scheduled for follow-up visits after 6 and 12 weeks of supplementation.

Connect with a study center

  • Exercise and Performance Nutrition Laboratory

    Saint Charles, Missouri 63301
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.